Interview with Stephen Turley, Managing Director, Lundbeck Limited (UK)
If we look at Lundbeck globally, the company has been doing very well. Last year was a record year for profits. From a UK perspective, can you provide an overview…
Address: Lundbeck House, Caldecotte Lake Drive, Caldecotte Lake, , Milton Keynes, MK7 8LG, United Kingdom
,United Kingdom
Tel: 0044 1908 649 966
Web: http://uk.lundbeck.com/uk/
Lundbeck is one of Denmark’s most research-intensive enterprises. We employ a total of 1,200 highly-trained specialists in our research and development units. Each year, Lundbeck ploughs back more than 20% of its revenue into research and development of new pharmaceuticals to improve treatment options for the millions of people around the world suffering from neurological disorders.
Lundbeck UK are specialists in psychiatry and pioneers in neurology. We are an international pharmaceutical organisation with a head office based in Milton Keynes, UK and a national field force. The office consists of; Sales & Marketing, Finance & Administration, Human Resources, Medical, and Business Intelligence.
Specialists in psychiatry, pioneers in neurology
As a pharmaceutical manufacturer, Lundbeck is unique in that we focus solely on the treatment of diseases of the central nervous system. Our aim is to be the world leader in the development of pharmaceuticals for psychiatric and neurological disorders, and are pioneers of new treatments and new approaches.
As specialists, our research and development is focused and concentrated. As specialists, we maintain close ties to our customers, establishing new links, building knowledge and developing new programmes. And as specialists, we are closer to the people suffering from psychiatric disorders and the people treating them.
UK Brand Name UK Generic Name
Azilect 1mg Tablets rasagiline
Circadin 2mg prolonged-release tablets melatonin
Cipralex 5mg/10mg/20mg Tablets escitalopram
Cipralex 10mg/ml Drops escitalopram
Cipramil 40mg/ml Drops citalopram
Cipramil 10mg/20mg/40mg Tablets citalopram
Clopixol Acuphase Injection zuclopenthixol
Clopixol Conc Injection zuclopenthixol
Clopixol Injection zuclopenthixol
Clopixol 2mg/10mg/25mg Tablets zuclopenthixol
If we look at Lundbeck globally, the company has been doing very well. Last year was a record year for profits. From a UK perspective, can you provide an overview…
Michelle Mitchell, CEO of the Multiple Sclerosis Society in the UK since 2013, discusses her charity’s aims; their focus on research and development; funding in the face of Brexit; and…
Recipient of the 2018 Brain Prize for research for groundbreaking research on the generic and molecular basis of Alzheimer’s Disease, the UCL’s Professor John Hardy discusses recent progress in dementia…
Tim de Gavre, country head of Sandoz UK, discusses the role of biosimilars in driving innovation, the threats and opportunities of Brexit to the biosimilars industry, and how Sandoz partners…
Mike Belton of the British Swiss Chamber of Commerce discusses the capabilities of the organization, its role within the British and Swiss investment ecosystem, and how Switzerland can act as…
John Smith, chief executive of the PAGB, the UK’s consumer healthcare industry association, discusses the potential impacts of Brexit on the PAGB’s members, the importance of consumer healthcare to the…
Sarah Haywood, CEO of MedCity, the life science cluster for London, Oxford and Cambridge in the southeast of England, discusses the organization’s strategy, key achievements, Brexit, and supporting SMEs. Why…
In an exclusive interview at the BioPharma Ambition Conference 2016 in Dublin, Sir Andrew Dillon, founding CEO of the UK National Institute for Health and Care Excellence (NICE), shares his…
Lord Philip Hunt, a former UK health minister during the Blair and Brown governments, shares his thoughts on procurement in healthcare, structural change and its impact, and how funds may…
British consultant, speaker and author, Richard Barker – a key opinion leader on UK healthcare – gives his take on the recently launched ‘Life Sciences Industrial Strategy’, the importance of…
Warwick Smith, director general of the British Generic Manufacturers Association (BGMA), discusses the potential impact of Brexit and recent policy changes on the British generics industry and extols the benefits…
Simon Gillespie of the British Heart Foundation (BHF), the UK’s leading national heart charity, outlines the organization’s mission, the issues surrounding translational research, and the potential impact of Brexit on…
Hilary Evans of Alzheimer’s Research UK (ARUK), the UK’s leading national research charity in the field of dementia, discusses her organization’s mission; the growing awareness of, and investment in, dementia…
See our Cookie Privacy Policy Here
